Prescription opioids increase the risk of falls, especially in the over 85s

Publicly released:
Australia; NSW
Photo by Guillermo Latorre on Unsplash
Photo by Guillermo Latorre on Unsplash

Taking prescription opioids could increase your chances of also taking a tumble, with new Australian research showing a link between the drugs and a higher risk of falls. The large study, of over 3.2 million adults, found that taking prescription opioids was linked to the risk of a fall-related trip to the emergency department. The study found there was an increased risk at all ages, but the authors say that people aged 85 years or older are at greatest risk.

Media release

From: The University of New South Wales

Study finds prescription opioids are associated with serious falls among adults of all ages.

Key points:
* Prescription opioid use is associated with an increased risk of serious falls leading to emergency department visits, hospital admissions, and death.
* The risk of falls was increased for adults of all ages and was highest for people aged 85 years and over.
* The risk of falls was higher during the first month of treatment, and when opioids were used at higher daily doses.
* This Australian-first study is one of the largest of its kind, including 3.2 million individuals who started an opioid medicine in NSW over a 16-year period.

A new study led by researchers at the National Drug and Alcohol Research Centre (NDARC), UNSW Sydney, has explored the association between prescription opioid use and falls.

The study, published in the journal JAMA Internal Medicine, examined falls that led to emergency department visits, hospital admissions, and death following a new opioid dispensing among 3.2 million people in the POPPY II study cohort. The POPPY II study is a retrospective cohort of NSW residents who initiated a prescription opioid through the Pharmaceutical Benefits Scheme between 2003 and 2018.

Lead author and Postdoctoral Research Fellow Dr Ria Hopkins said the study found that current opioid use was associated with a substantial risk of a serious fall among all age groups. Overall, one in ten people in the cohort experienced a serious fall during the study period, with higher rates among periods of opioid use compared to periods of no opioid use.

Compared to younger adults (18-44 years), the risk of a serious fall was six times higher for people aged 85 years and over during periods of opioid use, after accounting for other medicines and factors which may increase the risk of falls. Falls are a major cause of injury in Australia, and older people are at particular risk of serious negative consequences, including major injury and death.

“Although we expected to see increased fall risk among older individuals, we were surprised by how many falls there were among younger adults which resulted in emergency department visits and hospitalisations,” said Dr Ria Hopkins. “These findings demonstrate the need for doctors to be aware of and inform people of all ages about the risks of these types of injuries when starting or continuing opioid medicines.”

The month immediately following opioid initiation was also identified as a time of particularly high risk for serious falls among adults of all ages, and risk increased as daily doses of opioids increased.

Over the last thirty years, there have been concerns about the safety and appropriateness of opioid prescribing. One key concern is the potential for opioid use to increase the risk of falling among older adults due to the sedating effects of these medicines.
This study provides new data demonstrating that this risk is not exclusive to older adults and that fall prevention and education should be considered for all adults prescribed opioids, particularly when beginning treatment.

Senior author Scientia Associate Professor Natasa Gisev said “Our findings showed that falls are a relatively common adverse event among people using prescription opioids. Many falls are preventable, and whilst there is a large focus on interventions aimed at preventing falls among older adults, more work is needed to reduce the risk among younger adult populations.”

For reference: When reporting on drugs and alcohol, we encourage consultation of the Mindframe guidelines on ‘Communicating about alcohol and other drugs’ and ‘Communicating about suicide’ and the ‘Language Matters’ guide published by the NSW Users and AIDS Association.

We also encourage the inclusion of the following helpline information in all reporting:
People can access free and confidential advice about alcohol and other drugs by calling the National Alcohol and Other Drug Hotline on 1800 250 015.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).
Journal/
conference:
JAMA Internal Medicine
Research:Paper
Organisation/s: The University of New South Wales, National Drug and Alcohol Research Centre (NDARC)
Funder: This work was supported by an Australian National Health and Medical Research Council (NHMRC) project grant (#1138442) and UNSW Sydney Neuroscience, Mental Health, and Addiction research theme seed funding. Dr Degenhardt is supported by an NHMRC research fellowship (2016825). Dr Hopkins is supported by an NHMRC Postgraduate Scholarship (1190977) and a National Drug and Alcohol Research Centre (NDARC) PhD Scholarship. NDARC, UNSW Sydney, is supported by funding from the Australian Government Department of Health within the Drug and Alcohol Program.
Media Contact/s
Contact details are only visible to registered journalists.